Most compounds on this catalog act on a system that does not act back. A senolytic peptide disrupts a protein-protein interaction; the cell does not compensate by downregulating its own senescence program. A topical signal peptide instructs a fibroblast; the fibroblast has no mechanism for deciding it has been instructed enough.
The hormonal shelf is different, and the difference is structural rather than incidental. Every compound filed here is an endogenous signalling molecule — or a direct mimic of one — that sits inside a closed regulatory loop. The system it acts on measures its own output and adjusts. That single fact makes a variable matter here that barely registers anywhere else on the site: not what the molecule binds, but for how long and in what pattern it is present.
On this shelf, the same molecule at the same receptor can push an axis in opposite directions. That is not a paradox to be resolved. It is the class-defining property.
What is actually on the shelf
Three catalog entries are filed under hormonal: Gonadorelin, HCG, and HMG. As with the immune and cosmetic primers, a useful discussion requires pulling in two compounds filed elsewhere by mechanism: Kisspeptin-10 from the sexual-health shelf, which sits one tier above gonadorelin, and Oxytocin from cognitive-mood, which is a posterior-pituitary hormone by any reasonable classification.
HGH 191AA also belongs to the "hormone itself" category, but it sits on its own axis and was covered in the growth-hormone class primer.
Four of these five map onto tiers of one cascade — kisspeptin at the hypothalamic pulse generator, gonadorelin at the pituitary GnRH receptor, HCG and HMG at the gonadotropin tier. That tier map was laid out in the HPG axis explainer and is not worth re-arguing here. What matters for a category primer is the sorting principle the tier map doesn't capture.
The spine: pattern, not just presence
Gonadorelin is synthetic GnRH — the decapeptide pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH₂, identical to the hypothalamic releasing hormone, with a pyroglutamate N-terminus and a C-terminal amide that the sequence primer covers as termini modifications.
The hypothalamus does not secrete GnRH continuously. It releases it in discrete pulses, and the pituitary gonadotrope is built to read that rhythm. Deliver GnRH in a pulsatile pattern and the pituitary responds by secreting LH and FSH. Deliver the identical molecule continuously and the gonadotrope downregulates — receptor internalisation and desensitisation of the kind described in the receptor pharmacology primer — and gonadotropin output falls below baseline.
Same molecule. Same receptor. Opposite direction. The variable that decides which one happens is the temporal pattern of exposure.
This is not a theoretical curiosity. It is a validated principle with drugs on both sides of it. Pulsatile GnRH delivery has an established clinical literature in hypothalamic amenorrhea. Meanwhile, an entire approved drug class — the GnRH agonist depots such as leuprolide, goserelin and triptorelin — exists specifically to exploit the other limb: sustained receptor occupancy causing an initial flare followed by profound suppression of the axis. Those agents are used clinically to shut the HPG axis down, and they do it with agonists.
The reading consequence is sharp. For a compound on this shelf, "agonist" does not tell you the direction of the effect. Elsewhere on the catalog it broadly does.
The picture is not uniform up the axis, either. Work in the ewe measuring GnRH directly in hypophyseal portal blood found that portal GnRH release mirrored both pulsatile and continuous intravenous kisspeptin infusion (Caraty et al., Journal of Neuroendocrinology 2013;25:537–546) — so the desensitisation behaviour seen at the pituitary GnRH receptor should not be assumed to apply identically at KISS1R one tier up. The general lesson holds; the specific kinetics are receptor-by-receptor.
Oxytocin: the member that breaks the feedback rule
If the class spine is "closed loops with negative feedback," oxytocin is the honest exception, and including it makes the category clearer rather than messier.
Oxytocin is a cyclic nonapeptide with a Cys1–Cys6 disulfide and a C-terminal amide, synthesised in the hypothalamus and released from the posterior pituitary. But it is not the top of a three-tier axis with a downstream gland producing a hormone that feeds back to shut off production. Its classical physiology runs the other way: the Ferguson reflex, in which cervical and uterine stretch drives oxytocin release, which drives contraction, which increases stretch. That is a positive feedback loop — self-amplifying, terminated by the end of the event rather than by a rising inhibitory signal.
So the hormonal shelf contains both loop architectures. The useful generalisation is not "these compounds are all under negative feedback." It is that all of them are embedded in loops at all, and reading any result requires knowing which loop and which direction.
One shelf, four different meanings of "purity"
This category also happens to have the widest spread in molecular definition of anything on the site, which changes what documentation can tell you.
- Gonadorelin — a defined ten-residue peptide. Chemical synthesis, fixed target mass, an ordinary HPLC and MS package answers identity and purity in the usual way.
- Oxytocin — a defined nine-residue peptide, but cyclic. The disulfide is part of the identity, and disulfide integrity is not answered by a purity percentage; the reduced open-chain form differs by roughly 2 Da and the free-acid C-terminus by about 1 Da, both near-mass problems covered in reading a chromatogram and mass spectrum.
- HCG — a defined heterodimeric glycoprotein, but the glycans vary, so the "molecule" is a glycoform population and potency is assigned in International Units by bioassay against a reference standard rather than by chemical purity.
- HMG — not a single molecule at all. It is a standardised urinary fraction whose gonadotropin content and non-gonadotropin protein load are the meaningful questions. A purity percentage on a mixture is not a characterisation number.
The HCG vs HMG comparison works through the glycopeptide-mapping evidence in detail, and net peptide content covers why quantitation methods have to be named rather than assumed. The point for a class primer is narrower: four entries on one shelf require four different documentation packages, and a vendor that prints the same three analytical lines for all of them has produced a template, not a characterisation. That is the general principle behind everything on the /quality/ page.
Where engineering enters this class
On the metabolic shelf, molecular design is aimed at receptor count and at defeating clearance. On the growth-hormone shelf, it is aimed at half-life. On the hormonal shelf, the design variable that has actually been pursued in trials is something subtler: the duration and shape of the downstream signal.
The clearest published example is MVT-602, a kisspeptin receptor agonist. Abbara and colleagues (Journal of Clinical Investigation 2020;130:6739–6753) compared it against native kisspeptin-54 in healthy women and in women with PCOS or hypothalamic amenorrhea. The informative result is the shape of the response, not its size: the amplitude of the LH rise was similar to kisspeptin-54, but it peaked much later — 21.4 hours versus 4.7 hours — with correspondingly greater total LH exposure. In brain slices, the agonist produced a longer duration of GnRH neuron firing (115 versus 55 minutes).
The programme continued into two randomised, placebo-controlled dose-finding trials reported in Fertility and Sterility (Abbara et al., 2024;121:95–106), the phase-1 in healthy premenopausal women and the phase-2a in women undergoing minimal ovarian stimulation with triptorelin as an active comparator.
Read against the desensitisation discussion above, this is the class's central tension made concrete. A longer signal on an axis that responds to pattern is not automatically a bigger signal or a better one — duration interacts with the feedback loop, and whether that interaction is favourable is an empirical question rather than a mechanistic deduction. Note also the isoform distinction flagged in the sexual-health roundup: the comparator was kisspeptin-54, not the kisspeptin-10 decapeptide. For current synthesis of the pathway, see Koysombat et al., Physiological Reviews 2025;105:707–764.
The evidence inversion
Every other class primer on this site ends the same way: mechanistically interesting, human file thin or empty. This one ends in the opposite place, and the reading error runs in the opposite direction too.
These are among the most heavily studied molecules in the catalog. Oxytocin and the gonadotropins have decades of human clinical data, approved products, standardised assays and established reference ranges. Kisspeptin has a genuine investigational human file. Nothing here resembles the "preclinical-only, single research lineage" problem that dominates the longevity and healing-recovery shelves.
The trap is assuming that abundance transfers. A large clinical literature about a defined medical use is a large literature about that use — not general permission to extrapolate. HCG's file is built around specific indications. Oxytocin's obstetric file and its intranasal social-cognition research file are effectively separate bodies of evidence with different routes, different compartments and different outcomes — the latter reviewed in the sleep, mood and social peptides roundup, where the largest recent trials returned null primary endpoints. Kisspeptin remains investigational and is not an approved drug in the US.
The evidence hierarchy applies here exactly as it does everywhere else. The difference is only that on this shelf, the question to ask a citation is usually "about which use, in which population?" rather than "does a human study exist at all?"
Short FAQ
Why is oxytocin filed under cognitive-mood rather than hormonal? Catalog filing follows the research question most people arrive with, not the molecule's endocrine classification. Oxytocin is a posterior-pituitary hormone; the contemporary research literature that drives interest in it is largely about social cognition. Shelf placement is a navigation artifact, not a mechanistic claim — the same caveat applied to Dermorphin's healing-recovery filing.
Does "pulsatile versus continuous" apply to every peptide, or just this class? The principle is general — receptor desensitisation is ordinary GPCR pharmacology — but it is load-bearing here in a way it usually isn't. For most catalog compounds the system does not have a downstream output that regulates the input. On the HPG axis it does, which is why exposure pattern can flip the sign of the effect rather than merely blunt its size.
Why does HMG have no purity percentage worth quoting? Because it is a standardised biological fraction rather than a defined molecule, and its activity is assigned by bioassay against a reference standard. A purity figure describes how much of a sample is one identified compound; when the product is defined as a mixture, that number has no clean referent. The synthesis routes piece covers why extraction-derived products get a different analytical paradigm than synthetic ones.
Further compound pages and mechanism references are indexed in the library.
This article is educational and for the laboratory research community. Trulogic Labs products are sold for laboratory and research use only and are not for human consumption.